Personal opinion here, but I would say it a combination of factors:
1. Reduction in selling pressure from seller paying for options.
2. General optimism about biotech - DXB, CU6 and TLX are all doing very well.
3. Relief that the bonus option scheme was a success taking away fears of a capital raise.
4. Knowledge that the AML trial is now going to be funded.
RAC - Charts & Price Action, page-21113
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.75 |
Change
0.000(0.00%) |
Mkt cap ! $298.0M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 660 | $1.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.82 | 2000 | 1 |
View Market Depth
| Last trade - 09.47am 10/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |
Day chart unavailable